NHD Global
Metabolic & Weight Loss · Triple-receptor research
Scientific Product Dossier
Retatrutide is a research peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. Scientists study how these signals work together in appetite, glucose control and energy use. Human trials have measured substantial average weight changes with a specific clinical preparation. Those results describe the tested preparation and study conditions; they do not establish effects of NHD catalog material. Below, you can compare the research findings, available catalog variants and information needed for a research enquiry.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The highest studied retatrutide group had a mean weight reduction of 24.2% at week 48, versus 2.1% with placebo. This was a secondary endpoint in a phase 2 trial.
Gastrointestinal events were common, and heart-rate increases were reported. These are monitored trial outcomes, not a guarantee for catalogue material.
Read the primary studyThe published TRIUMPH-1 report randomized 2,339 adults with obesity without diabetes and followed treatment for 80 weeks. Mean weight reduction in the highest study group was 25.0%, versus 3.9% with placebo.
Use the published endpoint and analysis when reading these numbers. Earlier sponsor announcements used different reported estimates; separate trials are not a head-to-head comparison with tirzepatide.
Read the primary studyIn a phase 2 trial in type 2 diabetes, the highest retatrutide study group had a 2.02-percentage-point HbA1c reduction at week 24, versus 0.01 points with placebo.
Percentage points describe the change in the HbA1c value; they are not a percentage reduction in body weight or a treatment instruction.
Read the primary studyFDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
FDA also warns that “research purposes” wording does not convert an unapproved product into an approved medicine.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 15 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 30 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 40 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 60 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 100 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled, dose-ranging clinical research over 48 weeks.
View primary recordPrimary registry record for the Phase 2 obesity study, including design, enrollment and outcome framework.
View primary recordThird-party publications selected for direct relevance.
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
ClinicalTrials.gov record NCT04881760.
U.S. Food and Drug Administration. Content current through May 31, 2026.
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
Concise answers for researchers comparing identity, evidence and catalog variants.
Placebo-controlled trials measured body-weight change and HbA1c, a marker of average blood sugar. Participants receiving retatrutide lost substantially more weight on average than those receiving placebo, and HbA1c improved in a diabetes trial. These are group averages from the tested clinical formulation and protocol. They do not predict individual results or apply to NHD research vials, which have not been studied in humans.
GIP, GLP-1 and glucagon are hormone receptors involved in appetite, insulin release and energy use. Combining all three activities in a single peptide is the defining feature of retatrutide and the reason it is studied. Engaging more receptors does not automatically mean better or safer outcomes; both benefits and adverse effects must be measured in controlled trials.
The main areas covered here are weight reduction and blood-sugar control. The results come from clinical trials of a defined intervention. NHD catalogue material has not been tested in those trials.
No. It was the mean result of one study group at 48 weeks in the 2023 trial. Participants varied, and the trial also recorded adverse events.
No. It remains an investigational compound in clinical development.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. Retatrutide is one designed molecule that can activate three receptor types. That is different from mixing three separate ingredients. Match the full compound name and requested form when comparing research quotations.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
A close reading of retatrutide’s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.
Updated October 1, 2026
A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.
Updated October 1, 2026
A liver-fat result is easy to mistake for a body-weight result. This study used MRI to measure fat inside the liver. Here is how…
Updated October 9, 2026
A 275-person diabetes study used appetite questionnaires alongside weight measurements. Here is what those two types of evidence can—and cannot—tell us.
Updated October 10, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
Read the 338-person trial without confusing an average result with a promise.
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: RT5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
